









Märkte
/
Aktien
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

5.740USD

+0.100+1.77%

Trading geöffnet （ET）Kurse um 15 Minuten verzögert

526.87MMarktkapitalisierung

VerlustKGV TTM



Verrica Pharmaceuticals Inc

5.740

+0.100+1.77%

Übersicht Unternehmen Finanzen

Finanzen

mehr Informationen über Verrica Pharmaceuticals Inc Unternehmen

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Unternehmensinformationen

BörsenkürzelVRCA

Name des UnternehmensVerrica Pharmaceuticals Inc

IPO-datumJun 15, 2018

CEODr. Jayson Rieger

Anzahl der mitarbeiter71

WertpapierartOrdinary Share

GeschäftsjahresendeJun 15

Addresse44 West Gay Street

StadtWEST CHESTER

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl19380

Telefon14844533300

Websitehttps://verrica.com/

BörsenkürzelVRCA

IPO-datumJun 15, 2018

CEODr. Jayson Rieger

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jayson Rieger

President, Chief Executive Officer, Director

88.99K

+50.90%

Mr. David Zawitz

Chief Operating Officer

11.00K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

Dr. Lawrence Eichenfield, M.D.

Independent Director

Mr. John J. Kirby

Interim Chief Financial Officer, Interim Principal Financial Officer

Mr. Paul B. Manning

Chairman of the Board

Mr. Mark A. Prygocki, Sr.

Independent Director

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jayson Rieger

President, Chief Executive Officer, Director

88.99K

+50.90%

Mr. David Zawitz

Chief Operating Officer

11.00K

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

Dr. Gavin Corcoran

Independent Director

2.00

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

Dr. Lawrence Eichenfield, M.D.

Independent Director

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Fri, May 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Manning (Paul B.)

53.85%

Caligan Partners, LP

9.72%

Armistice Capital LLC

9.26%

BKB Growth Investments LLC

6.46%

Boothbay Fund Management, LLC

3.04%

Other

17.67%

Aktionäre

Anteil

Manning (Paul B.)

53.85%

Caligan Partners, LP

9.72%

Armistice Capital LLC

9.26%

BKB Growth Investments LLC

6.46%

Boothbay Fund Management, LLC

3.04%

Other

17.67%

Aktionärstypen

Aktionäre

Anteil

Individual Investor

57.67%

Hedge Fund

19.53%

Investment Advisor

6.74%

Corporation

6.74%

Investment Advisor/Hedge Fund

5.58%

Research Firm

0.28%

Venture Capital

0.06%

Bank and Trust

0.04%

Pension Fund

0.01%

Other

3.35%

Institutionelle Beteiligung

Aktualisiert: Tue, Jul 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q2

182

8.94M

96.65%

+3.24M

2025Q1

194

69.94M

75.99%

+19.16M

2024Q4

191

70.39M

77.72%

+35.42M

2024Q3

179

29.67M

67.28%

-5.27M

2024Q2

173

33.68M

79.75%

-1.13M

2024Q1

171

34.51M

82.01%

-2.46M

2023Q4

170

35.04M

83.66%

+1.56M

2023Q3

172

32.74M

78.91%

-2.85M

2023Q2

169

31.35M

77.69%

+2.98M

2023Q1

171

29.74M

73.94%

+2.67M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Manning (Paul B.)

31.38M

33.93%

+17.53M

+126.54%

Nov 26, 2024

Caligan Partners, LP

8.99M

9.72%

+1.56M

+21.04%

Mar 31, 2025

Armistice Capital LLC

8.57M

9.26%

-353.60K

-3.96%

Mar 31, 2025

BKB Growth Investments LLC

5.98M

6.46%

+5.98M

Nov 22, 2024

Boothbay Fund Management, LLC

2.81M

3.04%

+220.30K

+8.52%

Mar 31, 2025

The Vanguard Group, Inc.

2.36M

2.55%

+481.41K

+25.61%

Mar 31, 2025

Stalfort (John A)

1.87M

2.03%

+238.09K

+14.56%

Apr 01, 2025

BlackRock Institutional Trust Company, N.A.

1.12M

1.22%

+32.58K

+2.98%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.02M

1.1%

+541.22K

+113.40%

Mar 31, 2025

Rieger (Jayson)

889.88K

0.96%

+300.19K

+50.91%

Apr 01, 2025

Verbundene ETFs

Aktualisiert: Sat, Aug 2

Name

Anteil

Invesco NASDAQ Future Gen 200 ETF

iShares Russell 2000 Growth ETF

Global X Russell 2000 ETF

Proshares Ultra Russell 2000

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

Simplify Propel Opportunities ETF

iShares Russell 2000 ETF

ProShares Hedge Replication ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Invesco NASDAQ Future Gen 200 ETF

Anteil0%

iShares Russell 2000 Growth ETF

Anteil0%

Global X Russell 2000 ETF

Anteil0%

Proshares Ultra Russell 2000

Anteil0%

Avantis US Small Cap Equity ETF

Anteil0%

iShares Micro-Cap ETF

Anteil0%

Simplify Propel Opportunities ETF

Anteil0%

iShares Russell 2000 ETF

Anteil0%

ProShares Hedge Replication ETF

Anteil0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI

